1. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Issue 9 (25th February 2021) Authors: Provenzano, Robert; Shutov, Evgeny; Eremeeva, Liubov; Korneyeva, Svitlana; Poole, Lona; Saha, Gopal; Bradley, Charles; Eyassu, Meraf; Besarab, Anatole; Leong, Robert; Liu, Cameron S; Neff, Thomas B; Szczech, Lynda; Yu, Kin-Hung P Journal: Nephrology dialysis transplantation Issue: Volume 36:Issue 9(2021) Page Start: 1717 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study. Issue 2 (9th November 2021) Authors: Henry, David H.; Glaspy, John; Harrup, Rosemary; Mittelman, Moshe; Zhou, Amy; Carraway, Hetty E.; Bradley, Charles; Saha, Gopal; Modelska, Katharina; Bartels, Pamela; Leong, Robert; Yu, Kin‐Hung P. Journal: American journal of hematology Issue: Volume 97:Issue 2(2022) Page Start: 174 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗